Report LibraryAll Reports
Datamonitor Healthcare Oncology Disease Analysis: Head and Neck Cancer
November 24, 2023
The first immunotherapies approved for recurrent/metastatic HNSCCs are anti-PD-1/PD-L1 immune checkpoint inhibitors (ICIs) Keytruda (approved both as monotherapy and in combination with platinum chemotherapy) and Opdivo (approved only as monotherapy). In this setting, we expect that ICIs are used primarily for first-line patients, with Keytruda being favored over Opdivo.
This Datamonitor Healthcare report contains a Disease Analysis module.
Head and Neck Cancer